Furthermore, promoting the expression of FOXD3 is beneficial for the prognosis of patients with neuroblastoma (Li et al., 2013), whereas inhibiting FOXD3 expression is detrimental to the prognosis of breast cancer patients (Chu et al., 2014). The gene discussed is FOXD3; the disease is neuroblastoma.